Clinical Trial Update: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bemarituzumab added to chemotherapy and nivolumab versus chemotherapy and nivolumab in FGFR2b-overexpressing untreated advanced gastr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Bemarituzumab (bemarituzumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Amgen | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING